More about these trials below:
The T1DAL study (Inducing Remission in New-onset Type 1 Diabetes with Alefacept) tested whether an investigational drug called alefacept (also called Amevive®) was able to slow or halt the destruction of insulin-producing beta cells in newly-diagnosed type 1 diabetes patients. Alefacept is a biologic that inhibits the activation of T-cells, which are known to be important mediators in the pathogenesis of type 1 diabetes and other autoimmune diseases.
The 12 month follow-up results of T1DAL were published in Lancet Diabetes Endocrinol on September 23, 2003 and the 24 month follow-up results were published in the Journal of Clinical Investigation on July 20, 2015. Individuals with new-onset type 1 diabetes who took two courses of alefacept soon after diagnosis showed significantly lower decline in C-peptide production, an indicator of beta cell function, compared to placebo group. Rates of C-peptide decline varied among individuals in the alefacept group, but 30% showed no decline at all and were considered "complete responders." The patients who received alefacept had significantly lower insulin requirements and a significant 50% reduction in major hypoglycemic events.
The purpose of the AbATE study was to determine whether treatment with teplizumab could halt the progression of newly diagnosed type 1 diabetes. Teplizumab is a biologic that targets the T-cells that are responsible for the immune attack on beta cells.
After 2 years, the teplizumab-treated group showed significantly greater preservation of C-peptide, an indicator of beta cell function, compared to the control group (75% higher responses compared to control), meeting the study’s primary endpoint.